Achaogen Inc (AKAO) 11.11 $AKAO
Achaogen Announces Plazomicin Granted QIDP Designation by FDA
GlobeNewswire - Thu Jan 08, 4:30AM CST
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today announced that the Company's lead product candidate, plazomicin, has received Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). The QIDP designation was created by the Generating Antibiotic Incentives Now (GAIN) Act, which was part of the FDA Safety and Innovation Act (FDASIA) and provides certain incentives for the development of new antibiotics, including priority review and an additional five years of market exclusivity. The FDA granted fast track status for plazomicin in 2012.
AKAO: 11.11 (-0.27)
Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014
M2 - Wed Jan 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/2z3625/community) has announced the addition of the "Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Furiex Pharmaceuticals, Inc. - Galapagos NV - Novan, Inc. Drug Profiles - acorafloxacin - GLPG-1492 - NVN-4428 - SB-204 - Small Molecules to Inhibit Beta Lactamase for Bacterial Infections - Synthetic Peptide for Multi-Drug Resistant Bacterial Infections For more information visit http://www.researchandmarkets.com/research/2z3625/community
FURX: 104.77 (-1.41), AKAO: 11.11 (-0.27)
Achaogen (AKAO) Crumbles: Stock Falls by 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:34AM CST
Achaogen (AKAO) fell by nearly 7% in the last trading session amid huge volumes, reversing its recent uptrend, as the stock is now up nearly 30% in the past one month.
AKAO: 11.11 (-0.27), BIOD: 1.38 (-0.14)
Achaogen (AKAO) is in Overbought Territory: What's Next?
Achaogen Announces Plazomicin Granted QIDP Designation by FDA
GlobeNewswire - Thu Jan 08, 4:30AM CST
Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today announced that the Company's lead product candidate, plazomicin, has received Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). The QIDP designation was created by the Generating Antibiotic Incentives Now (GAIN) Act, which was part of the FDA Safety and Innovation Act (FDASIA) and provides certain incentives for the development of new antibiotics, including priority review and an additional five years of market exclusivity. The FDA granted fast track status for plazomicin in 2012.
AKAO: 11.11 (-0.27)
Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014
M2 - Wed Jan 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/2z3625/community) has announced the addition of the "Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Furiex Pharmaceuticals, Inc. - Galapagos NV - Novan, Inc. Drug Profiles - acorafloxacin - GLPG-1492 - NVN-4428 - SB-204 - Small Molecules to Inhibit Beta Lactamase for Bacterial Infections - Synthetic Peptide for Multi-Drug Resistant Bacterial Infections For more information visit http://www.researchandmarkets.com/research/2z3625/community
FURX: 104.77 (-1.41), AKAO: 11.11 (-0.27)
Achaogen (AKAO) Crumbles: Stock Falls by 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 7:34AM CST
Achaogen (AKAO) fell by nearly 7% in the last trading session amid huge volumes, reversing its recent uptrend, as the stock is now up nearly 30% in the past one month.
AKAO: 11.11 (-0.27), BIOD: 1.38 (-0.14)
Achaogen (AKAO) is in Overbought Territory: What's Next?
